Everything below concerns angiogenesis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
| Property | Value | Notes |
|---|---|---|
| Typical subjects | Rats and mice | Animal models |
| Common routes | Injection and oral | Route varies by study |
| Reported dose range | Microgram to milligram per kg | Not standardized across work |
| Frequent endpoints | Tissue repair, angiogenesis | Marker-dependent |
| Human evidence | Limited | Mostly small or preliminary studies |
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
=== 1960s–1980s === For several petty crimes, sixteen-year-old Olofsson was placed in a behavioural institution for young offenders in 1963. Olofsson and two other boys escaped from the institution in August 1965 and entered the country estate of Swedish Prime Minister Tage Erlander at Harpsund, where they stole grapes, cucumbers, and tomatoes from the greenhouse. They fled when the gardener discovered them. Three months later, Olofsson assaulted two police officers in Eskilstuna. On 4 February 1966, he was sentenced to three years in prison; this was his third sentence and his first real prison sentence. In late 1966, he made his first escape from the prison at Tidaholm. On 29 July 1966, police officers Ragnar Sandahl and Lennart Mathiasson responded to a burglary at a bicycle shop at Skjutsaregatan in Nyköping. Sandahl was shot and killed by Gunnar Norgren. The other burglar was Olofsson, who became a nationally known criminal. Norgren was arrested on 16 August that year in an apartment at Utåkersgatan 4 in Kålltorp, Gothenburg, and later confessed to the murder. The apartment belonged to a boyfriend of Olofsson's sister. Norgren gave up after the police fired several shots through the door to the apartment. Olofsson had escaped from the apartment before police entered and managed to elude them for two weeks but was eventually arrested on 25 August in Grimmaredsskogen in Västra Frölunda. Via telephone tapping, the police found out that Olofsson and his 20-year-old girlfriend were to meet at a special mountain hill in Grimmaredsskogen.
== See also == Ambient ionization Atmospheric pressure chemical ionization Atmospheric pressure photoionization Desorption atmospheric pressure photoionization Desorption electrospray ionization Electric glow discharge
=== HIV/AIDS === Baricitinib has been investigated for its potential to reduce the HIV reservoir and chronic inflammation in people infected with HIV. Preclinical studies in humanized mice and non-human primates have demonstrated that the drug can penetrate the blood-brain barrier and reach therapeutic concentrations in the central nervous system (CNS). In these models, baricitinib was associated with a reduction in cellular activation markers, lower frequencies of infected macrophages in the brain, and improvements in HIV-associated behavioral deficits. Research suggests that by blocking the JAK-STAT signaling pathway, the drug may limit the survival of infected cells and prevent the reseeding of viral reservoirs in sanctuary sites like the CNS, which are often poorly reached by standard antiretroviral therapy (ART). As of 2025, baricitinib is currently being evaluated in multiple Phase II clinical trials to assess its safety and efficacy as an adjunctive therapy to ART. One primary area of focus is its ability to decrease or clear the CNS reservoir, with ongoing trials monitoring changes in cerebrospinal fluid (CSF) viral DNA and neurocognitive function. Additional studies are examining its impact on systemic inflammation, cell survival pathways, and the delay of viral rebound during monitored treatment interruptions.
Sources: en.wikipedia.org
Immunoglobulin G (IgG) antibodies are large heterodimeric molecules, approximately 150 kDa and are composed of two kinds of polypeptide chain, called the heavy (~50kDa) and the light chain (~25kDa). The two types of light chains are kappa (κ) and lambda (λ). By cleavage with enzyme papain, the Fab (fragment-antigen binding) part can be separated from the Fc (fragment crystallizable region) part of the molecule. The Fab fragments contain the variable domains, which consist of three antibody hypervariable amino acid domains responsible for the antibody specificity embedded into constant regions. The four known IgG subclasses are involved in antibody-dependent cellular cytotoxicity. Antibodies are a key component of the adaptive immune response, playing a central role in both in the recognition of foreign antigens and the stimulation of an immune response to them. The advent of monoclonal antibody technology has made it possible to raise antibodies against specific antigens presented on the surfaces of tumors. Monoclonal antibodies can be acquired in the immune system via passive immunity or active immunity. The advantage of active monoclonal antibody therapy is the fact that the immune system will produce antibodies long-term, with only a short-term drug administration to induce this response. However, the immune response to certain antigens may be inadequate, especially in the elderly. Additionally, adverse reactions from these antibodies may occur because of long-lasting response to antigens.
== Overview == Human growth hormone occurs naturally in the human body where it functions by stimulating growth of essentially all tissues, including bone. Use of exogenous human growth hormone (HGH), via injection, was originally for medical purposes until athletes began abusing HGH with the goal of increasing their abilities. Before recombinant human growth hormone (rHGH) was developed in 1981, HGH was only available by extracting it from the pituitary glands of cadavers. The arrival of rHGH combined with other peptide hormone advancements has increased the availability of HGH on both the legitimate and black markets. The first description of the use of GH as a doping agent was Dan Duchaine's "Underground Steroid handbook" which emerged from California in 1982; it is not known where and when GH was first used this way. In 1989 the International Olympic Committee became the first to brand human growth hormone a banned substance. Although abuse of human growth hormone for athletic purposes is illegal in the U.S., over the past decade it appears that abuse of HGH is present in all levels of sport. This is fueled at least in part by the fact that HGH is more difficult to detect than most other performance-enhancing drugs, such as anabolic steroids. This is because rHGH has an identical amino acid sequence to the native isoform of the hormone while GH from cadavers is indistinguishable from endogenous GH.
In the war against the Marcomanni in 167, the town was hard pressed; its fortifications had fallen into disrepair during the long peace. Nevertheless, when in 168 Marcus Aurelius made Aquileia the principal fortress of the empire against the barbarians of the North and East, it rose to the pinnacle of its greatness and soon had a population of 100,000. Septimius Severus visited in 193. In 238, when the town took the side of the Senate against the emperor Maximinus Thrax, the fortifications were hastily restored, and proved of sufficient strength to resist for several months, until Maximinus himself was assassinated.
Sources: en.wikipedia.org
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.
Frequently measured outcomes include wound healing, blood vessel growth, and tissue repair markers. Some work examines gastrointestinal protection. The choice of endpoint depends on the model used.
Different routes of administration and different animal models require different amounts. Studies also use varied timelines and measurement methods. This variation makes it difficult to combine results into a single standardized figure.
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.